Evidence map›Paper›PMID 39367307›Full record

ArticleBMC biotechnology2024

Enhancing the biotransformation of progesterone to the anticancer compound testololactone by Penicillium chrysogenum Ras3009: kinetic modelling and efficiency maximization.

Marwa M Abdel-Kareem, Abdel-Nasser A Zohri, Abdel-Hamied M Rasmey, Heba Hawary

Abstract read
In one paragraph

Article in BMC biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marwa M Abdel-KareemDepartment of Botany and Microbiology, Faculty of Science, Sohag University, Sohag, EG-82524, Egypt.
Abdel-Nasser A ZohriDepartment of Botany and Microbiology, Faculty of Science, Assiut University, Assiut, EG-71516, Egypt.ORCID 0000-0002-6503-7133
Abdel-Hamied M RasmeyDepartment of Botany and Microbiology, Faculty of Science, Suez University, P.O.Box: 43221, Suez, Egypt. Abdel-Hamied.rasmey@sci.suezuni.edu.eg.
Heba HawaryDepartment of Botany and Microbiology, Faculty of Science, Suez University, P.O.Box: 43221, Suez, Egypt.ORCID 0000-0002-5053-3177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiotransformation of steroid compounds into therapeutic products using microorganisms offers an eco-friendly and economically sustainable approach to the pharmaceutical industry rather than a chemical synthesis way. The biotransformation efficiency of progesterone into the anticancer compound testololactone using Penicillium chrysogenum Ras3009 has been investigated. Besides, maximization of testololactone formation was achieved by studying the kinetic modelling and impact of some fermentation conditions on the biotransformation process.

resultsThe fungal strain Ras3009 was selected among twelve fungal strains as the most runner for the transformation of 81.18% of progesterone into testololactone. Ras3009 was identified phenotypically and genotypically as Penicillium chrysogenum, its 18 S rRNA nucleotide sequence was deposited in the GenBank database by the accession number OR480104. Studying the impact of fermentation conditions on biotransformation efficiency indicated a positive correlation between substrate concentration and testololactone formation until reaching the maximum velocity v

conclusionsFungi can be promising biocatalysts for steroid transformation into valuable chemicals and pharmaceutical compounds. The study revealed that the new fungal isolate P. chrysogenum Ras3009 possesses a great catalytic ability to convert progesterone into testololactone. Kinetic modelling analysis and optimization of the fermentation conditions lead to higher transformation efficiency and provide a better understanding of the transformation processes.

Indexed as

Antineoplastic AgentsBiotransformationPenicillium chrysogenumProgesteroneFermentationKineticsAntineoplastic AgentsProgesteroneGC-MS analysisKinetic modellingPharmaceutical compoundsProgesteroneSteroids biotransformationTestololactone

Identifiers

PMID39367307
PMCPMC11451084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.